Turmeric Supreme Pain Support
On sale on the US market (according to the DSLD)
Gaia Herbs, food supplement from the US market
Turmeric Supreme Pain Support (Gaia Herbs), a food supplement au code-barres 751063146524, is described by its US market label. The French and European rules we can apply to this label flag no particular point. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
No point flagged by the rules we apply.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Gaia Herbs
- Barcode
- 751063146524
- Form
- Capsule
- One serving
- 2 capsules
- Servings
- up to 3 servings per day
- Other ingredients (in English, as written)
- Glycerin, Water, Sunflower Lecithin, Hypromellose, Chlorophyll
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Calories | Other | 5 Calorie(s) |
| Total Carbohydrates | Carbohydrate | 2 Gram(s) |
| Turmeric Root Extract (Curcuma longa) | Plant | 32 mg |
| Curcuminoids | Other substance | 30 mg |
| Rosemary Leaf Supercritical Extract | Plant | 100 mg |
| Proprietary Extract Blend | Blend | 875 mg |
| Turmeric (Curcuma longa) | Plant | not stated |
| Wild Lettuce (Lactuca virosa) | Plant | not stated |
| Jamaican Dogwood | Plant | not stated |
| Feverfew (Tanacetum parthenium) | Plant | not stated |
| Devil's Claw | Plant | not stated |
| Black Pepper Fruit Supercritical Extract (Piper nigrum) | Plant | 10 mg |
| Ginger Root Supercritical Extract | Plant | 10 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Turmeric Supreme Pain
Entered into DSLD on 26 December 2020. Withdrawn from the US market on 22 December 2022 (according to the DSLD).- Active ingredient added : Black Pepper fruit Supercritical CO2 extract (10 mg)
- Active ingredient added : Devil's Claw extract (quantity not stated)
- Active ingredient added : Jamaican Dogwood extract (quantity not stated)
- Active ingredient added : organic Feverfew extract (quantity not stated)
- Active ingredient added : organic Ginger root supercritical Co2 extract (10 mg)
- Active ingredient added : organic Turmeric extract (quantity not stated)
- Active ingredient added : Wild Lettuce extract (quantity not stated)
- Active ingredient removed : Black Pepper Fruit Supercritical Extract (10 mg)
- Active ingredient removed : Devil's Claw (quantity not stated)
- Active ingredient removed : Feverfew (quantity not stated)
- Active ingredient removed : Ginger Root Supercritical Extract (10 mg)
- Active ingredient removed : Jamaican Dogwood (quantity not stated)
- Active ingredient removed : Turmeric (quantity not stated)
- Active ingredient removed : Wild Lettuce (quantity not stated)
- Same quantity, different name: Curcumins in this version; Curcuminoids on the displayed label (30 mg)
- Same quantity, different name: Rosemary leaf Supercritical CO2 extract in this version; Rosemary Leaf Supercritical Extract on the displayed label (100 mg)
- Same quantity, different name: Tumeric root extract in this version; Turmeric Root Extract on the displayed label (32 mg)
Official label: Turmeric Supreme
Entered into DSLD on 22 December 2019. Withdrawn from the US market on 28 September 2020 (according to the DSLD).- Active ingredient added : Black Pepper fruit Supercritical CO2 extract (10 mg)
- Active ingredient added : Devil's Claw extract (quantity not stated)
- Active ingredient added : Jamaican Dogwood extract (quantity not stated)
- Active ingredient added : organic Feverfew extract (quantity not stated)
- Active ingredient added : organic Ginger root supercritical Co2 extract (10 mg)
- Active ingredient added : organic Turmeric extract (quantity not stated)
- Active ingredient added : Wild Lettuce extract (quantity not stated)
- Active ingredient removed : Black Pepper Fruit Supercritical Extract (10 mg)
- Active ingredient removed : Devil's Claw (quantity not stated)
- Active ingredient removed : Feverfew (quantity not stated)
- Active ingredient removed : Ginger Root Supercritical Extract (10 mg)
- Active ingredient removed : Jamaican Dogwood (quantity not stated)
- Active ingredient removed : Turmeric (quantity not stated)
- Active ingredient removed : Wild Lettuce (quantity not stated)
- Same quantity, different name: Curcumins in this version; Curcuminoids on the displayed label (30 mg)
- Same quantity, different name: Rosemary leaf Supercritical CO2 extract in this version; Rosemary Leaf Supercritical Extract on the displayed label (100 mg)
- Same quantity, different name: Tumeric root extract in this version; Turmeric Root Extract on the displayed label (32 mg)
Official label: Turmeric Supreme Pain
Entered into DSLD on 22 December 2017. Withdrawn from the US market on 29 August 2019 (according to the DSLD).- Active ingredient removed : Total Carbohydrates (2 Gram(s))
- Same quantity, different name: Curcumins in this version; Curcuminoids on the displayed label (30 mg)
- Different quantity per serving : Calories: 10 Calorie(s) in this version; 5 Calorie(s) on the displayed label
Official label: Turmeric Supreme Pain
Entered into DSLD on 22 May 2015. Withdrawn from the US market on 5 August 2017 (according to the DSLD).- Active ingredient removed : Total Carbohydrates (2 Gram(s))
- Same quantity, different name: Curcumins in this version; Curcuminoids on the displayed label (30 mg)
- Different unit, without conversion : Calories: 10 {Calories} in this version; 5 Calorie(s) on the displayed label
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Turmeric Root Extract
Read the warning, when it applies and the studies cited
TURMERIC - CURCUMA LONGA - Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000)
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).
Sources cited by Health Canada (2)
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).
Sources cited by Health Canada (6)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).
Sources cited by Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).
Sources cited by Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Condition of application: All uses except for Source of antioxidants and Hepatoprotectant.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 26 September 2025
Turmeric -CURCUMA LONGA - Topical
Cautions and warnings
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Contraindications
Do not use on deep or puncture wounds, animal bites or serious burns.
- Feverfew
Read the warning, when it applies and the studies cited
FEVERFEW - TANACETUM PARTHENIUM
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).
Sources cited by Health Canada (2)
- Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).
Sources cited by Health Canada (1)
- Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.
Contraindications
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.
Do not use if you are pregnant or breastfeeding (EMA 2020).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: All products.
Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).
Sources cited by Health Canada (2)
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).
Sources cited by Health Canada (3)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
- Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Gaia Herbs
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Turmeric Supreme Pain Support (Gaia Herbs): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/751063146524-turmeric-supreme-pain-support-gaia-herbs, updated 20 June 2024.